• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[糖尿病中的血脂异常:意义、诊断与治疗]

[Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment].

作者信息

Keller U, Golay A, Pometta D

机构信息

Abt. für Endokrinologie und Stoffwechsel, Kantonsspital, Basel.

出版信息

Schweiz Rundsch Med Prax. 1990 Oct 9;79(41):1199-204.

PMID:2237046
Abstract

Dyslipidemias are frequent in diabetic subjects: they increase the risk for atherosclerosis, in addition to the risk of diabetes mellitus per se. The pathogenesis of dyslipidemias differs between type I and type II diabetes: untreated type I diabetic subjects demonstrate frequently increased triglyceride concentrations due to diminished removal of triglyceride-containing particles, as a result of diminished activity of lipoprotein lipase. In addition, more triglycerides are produced due to increased lipolysis and increased free fatty acid supply to the liver. Type II diabetic subjects demonstrate very low density lipoprotein (VLDL) over-production due to obesity, insulin resistance and caloric overconsumption. In addition, triglyceride removal may be diminished due to diminished lipoprotein lipase activity when diabetes mellitus is poorly controlled. In addition, high density lipoprotein (HDL) is frequently lowered. During decompensation low density lipoprotein (LDL) concentrations may also increase. LDL particle composition is frequently abnormal. A severe dyslipidemia in diabetes mellitus is frequently a combined effect of diabetes mellitus and a congenital lipoprotein abnormality. The evaluation and treatment of dyslipidemias in diabetic subjects should be performed similarly to non-diabetics according to the guidelines published recently by the Working Group 'Lipids' of the Swiss Foundation of Cardiology. Additional accents in diabetic subjects are necessary. It is recommended that serum cholesterol, triglycerides and HDL are determined in every patient when diabetes mellitus is diagnosed. If serum cholesterol is greater than 6.5 mmol/l and the cholesterol/HDL-ratio is greater 6.5, dietary treatment should be reinforced; if its effect is insufficient, drug therapy should be considered.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

血脂异常在糖尿病患者中很常见

除了糖尿病本身的风险外,还会增加动脉粥样硬化的风险。I型和II型糖尿病患者血脂异常的发病机制不同:未经治疗的I型糖尿病患者由于脂蛋白脂肪酶活性降低,含甘油三酯颗粒的清除减少,常常出现甘油三酯浓度升高。此外,由于脂肪分解增加和肝脏游离脂肪酸供应增加,会产生更多的甘油三酯。II型糖尿病患者由于肥胖、胰岛素抵抗和热量摄入过多,会出现极低密度脂蛋白(VLDL)产生过多。此外,当糖尿病控制不佳时,脂蛋白脂肪酶活性降低可能会导致甘油三酯清除减少。此外,高密度脂蛋白(HDL)常常降低。在失代偿期间,低密度脂蛋白(LDL)浓度也可能升高。LDL颗粒组成常常异常。糖尿病患者严重的血脂异常常常是糖尿病和先天性脂蛋白异常共同作用的结果。根据瑞士心脏病学基金会“脂质”工作组最近发布的指南,糖尿病患者血脂异常的评估和治疗应与非糖尿病患者类似。糖尿病患者需要额外关注。建议在诊断糖尿病时,对每位患者进行血清胆固醇、甘油三酯和HDL检测。如果血清胆固醇大于6.5 mmol/l且胆固醇/HDL比值大于6.5,则应加强饮食治疗;如果效果不佳,则应考虑药物治疗。(摘要截选于250字)

相似文献

1
[Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment].[糖尿病中的血脂异常:意义、诊断与治疗]
Schweiz Rundsch Med Prax. 1990 Oct 9;79(41):1199-204.
2
Statins and diabetes.他汀类药物与糖尿病
Semin Vasc Med. 2004 Nov;4(4):321-32. doi: 10.1055/s-2004-869589.
3
Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.糖尿病患者的血脂异常:分类及治疗的风险与益处
Pharmacotherapy. 1995 May-Jun;15(3):317-37.
4
Pharmacologic treatment of type 2 diabetic dyslipidemia.2型糖尿病血脂异常的药物治疗。
Pharmacotherapy. 2004 Dec;24(12):1692-713. doi: 10.1592/phco.24.17.1692.52340.
5
[Disorders of lipid metabolism in diabetes mellitus].
Wien Med Wochenschr Suppl. 1989;105:9-17.
6
[Dyslipidemia in diabetes mellitus].[糖尿病中的血脂异常]
Ned Tijdschr Geneeskd. 2001 Apr 21;145(16):769-74.
7
Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.辛伐他汀对2型糖尿病患者的降脂作用。
Indian Heart J. 2001 Mar-Apr;53(2):172-6.
8
Treatment of diabetic dyslipoproteinemia.糖尿病血脂异常蛋白血症的治疗。
Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):239-45. doi: 10.1055/s-2003-41748.
9
[Lipid-lowering therapy in patients with type-2 diabetes mellitus].
Orv Hetil. 2003 Mar 23;144(12):557-61.
10
Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.血液透析中的脂蛋白改变:糖尿病患者与非糖尿病患者的差异
Metabolism. 2003 Jan;52(1):116-21. doi: 10.1053/meta.2003.50018.

引用本文的文献

1
Diallyl trisulfide attenuates hyperglycemia-induced endothelial apoptosis by inhibition of Drp1-mediated mitochondrial fission.二烯丙基三硫醚通过抑制 Drp1 介导线粒体分裂来减轻高血糖诱导的内皮细胞凋亡。
Acta Diabetol. 2019 Nov;56(11):1177-1189. doi: 10.1007/s00592-019-01366-x. Epub 2019 May 21.